Hemostemix completes private placement of subscription receipts and rights offering

August 25, 2017

On August 25, 2017, clinical-stage biotechnology company Hemostemix Inc. (TSXV: HEM) announced that it had raised gross proceeds of approximately $6.4 million from its previously announced brokered private placement of subscription receipts, a related non-brokered private placement of subscription receipts and a rights offering which expired on August 11, 2017.

PI Financial Corp. acted as exclusive agent, sole bookrunner and exclusive soliciting dealer for and on behalf of Hemostemix with respect to these transactions.

Miller Thomson advised PI Financial with a team that included Kevin Sorochan, Greg Smith and Erika Lai (securities) and Lisa Sim (IP).